Summary
Definition
History and exam
Key diagnostic factors
- upper extremity weakness
- stiffness, with poor coordination and balance
- spastic, unsteady gait
- painful muscle spasms
- difficulties arising from chairs and climbing stairs
- foot drop
- stiffness and decreased balance with impact on gait
- head drop
- progressive difficulties maintaining erect posture, with stooping
- muscle atrophy
- increased lumbar lordosis and tendency for abdominal protuberance
- hyperreflexia
- dyspnea
- coughing and choking on liquids (including secretions) and eventually on food
- strained, slow speech
- slurred, nasal, and, at times, dysphonic speech
- hypophonic speech
Other diagnostic factors
- propensity for falls
- sialorrhea and drooling
- inappropriate bursts of crying or laughing
- cognitive impairment
- features of frontotemporal dementia
Risk factors
- genetic predisposition or family history
- age >40 years
- military service
- professional athletic activity
- cigarette smoking
- agricultural chemical exposure
- lead exposure
Diagnostic tests
1st tests to order
- clinical diagnosis
Tests to consider
- electromyography (EMG) and nerve conduction studies
- repetitive nerve stimulation
- MRI brain and spine
- anti-GM1 antibodies
- voltage-gated calcium-channel antibodies
- acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) antibodies
- vitamin B₁₂
- creatine kinase
- lumbar puncture
- HIV test
- genetic testing
Treatment algorithm
all patients
Contributors
Authors
Christen Shoesmith, MD, FRCPC
Associate Professor of Neurology
Clinical Neurological Sciences
London Health Sciences Centre
London
Ontario
Canada
Disclosures
CS has received honoraria from Mitsubishi Tanabe Pharma Canada for participating in scientific medical advisory boards and for presenting at ALS CME events. She has also received stipends for consultancy work for Biogen. She is the chair of the CALS (Canadian ALS Research Network) and in that capacity sits on the scientific medical advisory board for ALS Canada. She is the site PI for several multicenter clinical trials, including trials sponsored by Mitsubishi Tanabe, AL-S Pharma, Sanofi, Calico, and Cytokintetics. CS is an author of references cited in this topic.
Acknowledgements
Dr Christen Shoesmith would like to gratefully acknowledge Professor Christopher J. McDermott, Dr Laura Simionescu, and Dr Jeremy Shefner, previous contributors to this topic.
Disclosures
CJM received fees for membership of data monitoring committees from Orion Pharma and Orphazyme. LS and JS declare that they have no competing interests.
Peer reviewers
William S. David, MD, PhD
Associate Professor of Neurology
Harvard Medical School
Boston
MA
Disclosures
WSD declares that he has no competing interests.
Leo McCluskey, MD MBE
Associate Professor of Neurology
University of Pennsylvania
Philadelphia
PA
Disclosures
LM declares that he has no competing interests.
Martin R. Turner, MA, MBBS, PhD, MRCP
MRC/MNDA Lady Edith Wolfson Clinician Scientist & Honorary Consultant Neurologist
Oxford University Department of Clinical Neurology
John Radcliffe Hospital
Oxford
UK
Disclosures
MRT is a co-author of "Motor Neuron Disease – A Practical Manual" (Oxford University Press, 2010), which is a summary of his own understanding and practice, and which strongly influenced the recommendations for revision of the current article. He receives a proportion of royalties derived from sales of this book.
Differentials
- Cervical spondylosis with myelopathy and radiculopathy
- Multifocal motor neuropathy
- Inclusion body myositis
More DifferentialsGuidelines
- Evidence-based consensus guidelines for ALS genetic testing and counseling
- Respiratory management of patients with neuromuscular weakness
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer